IPSEN (OTCMKTS:IPSEY – Get Free Report) has received an average rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company.
A number of research firms have issued reports on IPSEY. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays upgraded shares of IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th.
Read Our Latest Analysis on IPSEN
IPSEN Trading Up 0.0%
Shares of IPSEY opened at $46.81 on Tuesday. IPSEN has a 1-year low of $34.34 and a 1-year high of $51.10. The firm has a fifty day simple moving average of $43.23 and a two-hundred day simple moving average of $45.52.
About IPSEN
IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.
See Also
- Five stocks we like better than IPSEN
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
